ARHGAPs, or Rho GTPase activating proteins, are a family of proteins that regulate Rho GTPases, which are critical for cell signaling. Rho GTPases are molecular switches that control various cellular processes, including cytoskeletal dynamics, cell migration, and proliferation. They cycle between an active GTP-bound state and an inactive GDP-bound state. ARHGAP proteins facilitate the transition of Rho GTPases from their active to inactive form by increasing their intrinsic GTPase activity. This regulation is crucial for maintaining cellular homeostasis and responding to extracellular signals. Dysregulation of Rho GTPase signaling can lead to various diseases, including cancer, underscoring the importance of ARHGAPs in cell biology.
Targeting ARHGAPs for disruption or inhibition has emerged as a potential strategy in diseases where Rho GTPase signaling is aberrant. Inhibiting specific ARHGAPs can modulate the activity of Rho GTPases, thereby altering cellular behaviors that contribute to disease progression. For example, in cancer, targeting ARHGAPs could disrupt tumor cell migration and invasion. However, this approach requires careful consideration of the specific ARHGAP and tissue context, as Rho GTPases play diverse roles in different cell types. Additionally, targeting ARHGAPs poses challenges in achieving specificity and avoiding unintended effects on normal cellular functions.
VOIR ÉGALEMENT...
| Nom du produit | CAS # | Ref. Catalogue | Quantité | Prix HT | CITATIONS | Classement |
|---|---|---|---|---|---|---|
Fasudil, Monohydrochloride Salt | 105628-07-7 | sc-203418 sc-203418A sc-203418B sc-203418C sc-203418D sc-203418E sc-203418F | 10 mg 50 mg 250 mg 1 g 2 g 5 g 10 g | $18.00 $32.00 $85.00 $165.00 $248.00 $486.00 $910.00 | 5 | |
Inhibiteur de ROCK qui peut stabiliser l'activité de ARHGAP en diminuant la rétroaction de la voie. | ||||||
H-1152 dihydrochloride | 451462-58-1 | sc-203592 sc-203592A | 1 mg 5 mg | $102.00 $357.00 | 7 | |
Un autre inhibiteur de la Rho kinase qui pourrait potentiellement influencer les actions régulatrices de ARHGAP39 sur les Rho GTPases. | ||||||
EHT 1864 | 754240-09-0 | sc-361175 sc-361175A | 10 mg 50 mg | $209.00 $872.00 | 12 | |
Inhibiteur de Rac1 qui pourrait réduire la signalisation médiée par ARHGAP en stabilisant Rac1 inactif. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Inhibe Trio, un GEF, modifiant potentiellement l'activité GTPase médiée par ARHGAP. | ||||||
Rhosin | 1173671-63-0 | sc-507401 | 25 mg | $555.00 | ||
Inhibe sélectivement la liaison de RhoA au GEF, ce qui pourrait moduler les effets régulateurs de ARHGAP. | ||||||
Inhibiteur Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor | 509093-47-4 | sc-204013 | 5 mg | $160.00 | 2 | |
inhibiteur spécifique de l'activité de Cdc42, pourrait ajuster l'impact régulateur d'ARHGAP. | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | $115.00 | ||
Cdc42, ce qui pourrait affecter les processus en aval régulés par ARHGAP. | ||||||
PAC 1 | 315183-21-2 | sc-203174 sc-203174A | 10 mg 50 mg | $129.00 $525.00 | 1 | |
Inhibe les cytohésines, ce qui pourrait influencer indirectement l'activité de l'ARHGAP. | ||||||
RKI-1447 | 1342278-01-6 | sc-472590 | 1 mg | $330.00 | ||
Inhibe l'interaction entre JMY et RhoA, influençant ainsi indirectement l'activité de ARHGAP dans la voie Rho GTPase. | ||||||